StreetAlpha.app
Home › Stocks › VIR

Vir Biotechnology, Inc. (VIR)

Healthcare
Members
LATEST PRICE

Vir Biotechnology develops product candidates for serious infectious diseases and cancer. VIR reports earnings on Wed, Nov 4, 2026.

Prices, price targets and earnings estimates for VIR are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is VIR in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 4
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated VIR in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for VIRThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
HC Wainwright & Co.Maintained
Oct 7Buy
Morgan StanleyMaintained
Jun 11Buy
Leerink PartnersMaintained
Jun 3Buy
DateFirmActionRatingPrice target
Oct 7HC Wainwright & Co.MaintainedBuy
Jun 11Morgan StanleyMaintainedBuy
Jun 3Leerink PartnersMaintainedBuy
Loading…

Whale Options Flow

90D

No whale options trades in VIR in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VIR is in one of them and how their past VIR trades turned out.

See how it works→ View all auto pilots→
VIR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VIR in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Vir Biotechnology

Vir Biotechnology is a biotechnology company based in San Francisco, California. It is developing product candidates, none yet approved, for serious infectious diseases and cancer, built on several technology platforms. The company also works with other drugmakers through collaboration and licensing agreements, both acquiring rights to some candidates and granting rights to others for further development.

Headquarters
San Francisco, CA
Founded
2016
Summary based on the company’s 2026 annual report (10-K) ↗